CN103635487B - 选择性消除侵蚀性细胞 - Google Patents

选择性消除侵蚀性细胞 Download PDF

Info

Publication number
CN103635487B
CN103635487B CN201280029746.4A CN201280029746A CN103635487B CN 103635487 B CN103635487 B CN 103635487B CN 201280029746 A CN201280029746 A CN 201280029746A CN 103635487 B CN103635487 B CN 103635487B
Authority
CN
China
Prior art keywords
antibody
cells
nkg2a
seq
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280029746.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103635487A (zh
Inventor
K.塞德斯特雷姆
E.D.加斯加亚尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN103635487A publication Critical patent/CN103635487A/zh
Application granted granted Critical
Publication of CN103635487B publication Critical patent/CN103635487B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280029746.4A 2011-06-17 2012-06-18 选择性消除侵蚀性细胞 Active CN103635487B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11170402.9 2011-06-17
EP11170402 2011-06-17
US201161501533P 2011-06-27 2011-06-27
US61/501533 2011-06-27
PCT/EP2012/061583 WO2012172102A1 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells

Publications (2)

Publication Number Publication Date
CN103635487A CN103635487A (zh) 2014-03-12
CN103635487B true CN103635487B (zh) 2016-10-12

Family

ID=44904625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280029746.4A Active CN103635487B (zh) 2011-06-17 2012-06-18 选择性消除侵蚀性细胞

Country Status (11)

Country Link
US (4) US9512228B2 (enExample)
EP (1) EP2721068B1 (enExample)
JP (1) JP6334395B2 (enExample)
KR (1) KR102047248B1 (enExample)
CN (1) CN103635487B (enExample)
AU (1) AU2012268939B2 (enExample)
BR (1) BR112013032217B1 (enExample)
CA (1) CA2838220C (enExample)
MX (1) MX342131B (enExample)
RU (1) RU2617056C2 (enExample)
WO (1) WO2012172102A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
EP4368205A1 (en) 2014-09-16 2024-05-15 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016062851A1 (en) * 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2019175182A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
EP3793607A1 (en) 2018-05-15 2021-03-24 MedImmune Limited Treatment of cancer
WO2020205440A1 (en) * 2019-03-29 2020-10-08 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels
CA3181963A1 (en) * 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
EP4221752A4 (en) 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
CN114524876B (zh) * 2020-11-23 2025-12-05 南京北恒生物科技有限公司 靶向nkg2a的抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107269A (zh) * 2004-12-28 2008-01-16 依奈特制药公司 抗nkg2a的单克隆抗体
CN101484471A (zh) * 2006-06-30 2009-07-15 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
CN101952317A (zh) * 2008-01-24 2011-01-19 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112484A (ja) 1989-09-26 1991-05-14 Nisshin Seito Kk 新規制限酵素及びその製造方法
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH03112484U (enExample) 1990-03-02 1991-11-18
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
AU2002325333B2 (en) 2001-07-19 2008-04-03 Innate Pharma NTB-A, a surface molecule involved in natural killer cells activity
WO2003011895A2 (en) 2001-07-31 2003-02-13 Soederstroem Karl Petter Compositions and methods for modulation of immune responses
WO2003095965A2 (en) 2002-05-13 2003-11-20 Envirotech Products Limited Tank valve testing method
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
CN1751236A (zh) 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
ES2526343T3 (es) * 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
CA2623109C (en) * 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CN103635487B (zh) * 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
AU2015307316A1 (en) 2014-08-28 2017-03-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc CD94/NKG2A and/or CD94/NKG2B antibody, vaccine combinations
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
EP4368205A1 (en) 2014-09-16 2024-05-15 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107269A (zh) * 2004-12-28 2008-01-16 依奈特制药公司 抗nkg2a的单克隆抗体
CN101484471A (zh) * 2006-06-30 2009-07-15 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
CN101952317A (zh) * 2008-01-24 2011-01-19 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体

Also Published As

Publication number Publication date
BR112013032217B1 (pt) 2021-01-19
WO2012172102A1 (en) 2012-12-20
US20230416374A1 (en) 2023-12-28
AU2012268939B2 (en) 2017-05-04
RU2617056C2 (ru) 2017-04-19
KR102047248B1 (ko) 2019-11-21
KR20140037918A (ko) 2014-03-27
US20170073417A1 (en) 2017-03-16
EP2721068B1 (en) 2018-12-05
CA2838220C (en) 2020-07-21
CA2838220A1 (en) 2012-12-20
RU2013158625A (ru) 2015-07-27
JP2014519522A (ja) 2014-08-14
JP6334395B2 (ja) 2018-05-30
CN103635487A (zh) 2014-03-12
MX342131B (es) 2016-09-14
US11697687B2 (en) 2023-07-11
US20140161802A1 (en) 2014-06-12
BR112013032217A2 (pt) 2016-11-22
EP2721068A1 (en) 2014-04-23
US9512228B2 (en) 2016-12-06
US20200109206A1 (en) 2020-04-09
MX2013014203A (es) 2014-01-20

Similar Documents

Publication Publication Date Title
US20230416374A1 (en) Selective elimination of erosive cells
TWI564305B (zh) 治療性抗體
AU2012268939A1 (en) Selective elimination of erosive cells
ES2630328T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
EP3694552A1 (en) Anti-lap antibodies and uses thereof
KR20150018533A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
JP2017530119A (ja) リンパ球における阻害経路の中和
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
CA2938945A1 (en) Combination treatment for multiple sclerosis
US20240294634A1 (en) Treatment of cancer with ilt-2 inhibitors
JP2024097985A (ja) 抗ｇｉｔｒ抗体およびその使用
US20140065154A1 (en) Tlr3 binding agents
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
ES2719849T3 (es) Eliminación selectiva de células erosivas
RU2782950C2 (ru) Подкожное введение анти-cd38 антител
WO2025024265A1 (en) Methods of assessing citrullination and activity of pad4 modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant